Protara shares spike after cell therapy shows high response rate, no severe side effects in bladder cancer trial

At six months, Protara Therapeutics’ investigational cell therapy elicited a complete response (CR) rate of 72% among 18 patients with bladder cancer, data that sent the biotech’s shares surging.